F M Investments LLC Has $4.54 Million Stock Holdings in Amgen Inc. (NASDAQ:AMGN)

F M Investments LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 28.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,411 shares of the medical research company’s stock after purchasing an additional 3,818 shares during the quarter. F M Investments LLC’s holdings in Amgen were worth $4,538,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. lifted its holdings in Amgen by 5.2% in the third quarter. Sunbelt Securities Inc. now owns 4,672 shares of the medical research company’s stock valued at $1,505,000 after buying an additional 230 shares during the period. Soltis Investment Advisors LLC raised its position in shares of Amgen by 17.4% during the 3rd quarter. Soltis Investment Advisors LLC now owns 2,376 shares of the medical research company’s stock valued at $766,000 after acquiring an additional 352 shares during the last quarter. Virtu Financial LLC acquired a new position in shares of Amgen in the 3rd quarter valued at $1,588,000. Morse Asset Management Inc bought a new position in shares of Amgen in the 3rd quarter worth $806,000. Finally, Tudor Financial Inc. acquired a new stake in shares of Amgen during the third quarter worth $3,281,000. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling at Amgen

In other news, EVP David M. Reese sold 25,225 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the sale, the executive vice president now owns 36,922 shares of the company’s stock, valued at approximately $11,240,533.68. This represents a 40.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 over the last ninety days. 0.69% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have weighed in on AMGN shares. Royal Bank of Canada reissued an “outperform” rating and issued a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. Piper Sandler Companies reiterated an “overweight” rating and issued a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Truist Financial decreased their price objective on shares of Amgen from $333.00 to $298.00 and set a “hold” rating for the company in a report on Wednesday, January 8th. Citigroup reaffirmed a “neutral” rating on shares of Amgen in a research note on Wednesday, February 5th. Finally, Morgan Stanley lifted their price target on shares of Amgen from $328.00 to $330.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and an average target price of $315.22.

Amgen Price Performance

NASDAQ AMGN opened at $281.41 on Friday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm’s 50 day moving average is $304.39 and its 200-day moving average is $295.46. The company has a market capitalization of $151.17 billion, a PE ratio of 37.27, a price-to-earnings-growth ratio of 2.63 and a beta of 0.59. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a dividend of $2.38 per share. The ex-dividend date is Friday, May 16th. This represents a $9.52 annualized dividend and a yield of 3.38%. Amgen’s dividend payout ratio (DPR) is presently 126.09%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.